Select Page

South Delhi Pharma, New Delhi, India

VITRAKVI (larotrectinib) oral solution.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

VITRAKVI is a prescription medicine. VITRAKVI used for adult and pediatric patients with solid tumors.

INDICATIONS AND USAGE
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have no satisfactory alternative treatments or that have progressed following treatment.

DOSAGE FORMS & STRENGTHS
• Capsules: 25 mg, 100 mg
• Oral Solution: 20 mg/mL
Manufactured By: HealthCare Pharmaceuticals Inc.
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “VITRAKVI® (larotrectinib) oral solution” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.

Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion. Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.

Larotrectinib was approved for medical use in the European Union in September 2019. It was approved for medical use in Australia in August 2020.

1 review for VITRAKVI (larotrectinib) oral solution.

There are no reviews yet.

Be the first to review “VITRAKVI (larotrectinib) oral solution.”

Your email address will not be published.